Enveric Biosciences Q1 net loss narrows to $2.2M; progresses EB-003 IND timeline

Enveric Biosciences, Inc.

2025-Q1 EPS reported -$1.22

Net loss $2.2M in Q1 2025 vs $2.5M in Q1 2024; diluted loss per share $1.22 vs $9.21.
Cash and equivalents $4.3M at March 31, 2025, after closing $5M public offering.
New U.S. patent for EVM401 Series (mescaline derivatives) and EB-003 IP expanded.
Signed two licensing agreements for cannabinoid-COX-2 conjugates with Restoration Biologics.
Targeting FDA IND submission for EB-003 by end of Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.